A trial to asses RPL554 dry powder inhaler formulation in patients with moderate to severe Chronic-obstructive-pulmonary-disease
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 17 Dec 2018 According to a Verona Pharma media release, status changed from planning to recruiting.
- 17 Dec 2018 According to a Verona Pharma media release, data from the single dose part of the study are expected during the first half of 2019.
- 18 Nov 2018 New trial record